Targeting the PD-L1/PD-1 axis and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) with ICIs has shown significant improvements in survival outcomes for patients with NSCLC (238). The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.